GAITHERSBURG, Md., July 7 /PRNewswire/ -- Panacea Pharmaceuticals, Inc. is
pleased to announce the election of Ambassador Diana Lady Dougan to its Board
of Directors. Ambassador Dougan will be taking the place of Ginger S. Johnson,
PhD, who has completed her three-year term.
Ambassador Dougan's career spans more than 30 years in senior management,
technology and foreign policy positions including appointments by both
Republican and Democratic Presidents in full U.S. Senate confirmed positions.
"It's a pleasure to welcome Ambassador Dougan to our Board of Directors.
Her vast and diverse experience in technology, foreign policy, and
international business development and cooperation will facilitate our global
partnering strategy," stated Hossein A. Ghanbari, PhD, Chairman, CEO, and
Chief Scientific Officer of the Company. "On behalf of our Board, management,
and investors, we also wish to thank Ginger for her efforts and contributions
the last three years."
Ambassador Dougan spearheads a diversity of government-industry
initiatives involving information technology, policy, and application issues
internationally. She is currently Chairman of the Cyber Century Forum (501c3);
Senior Advisor at the Center for Strategic & International Studies (CSIS), one
of America's pre-eminent think tanks based in Washington, D.C.; and Co-chair
of the Governing Board of the Center for Information Infrastructure & Economic
Development (CIIED) based in Beijing under the auspices of the prestigious
Chinese Academy of Social Sciences (CASS).
During her six years as the first statutory U.S. Coordinator for
International Communications and Information Policy and administratively as
Assistant Secretary of State from 1982-1988, Ambassador Dougan oversaw
international telecom, broadcast, and information technology policy interests
on behalf of 14 federal agencies. She spearheaded a wide range of
organizational and policy reforms including: competition in international
satellites, international credit card protocols, the OECD Trans border Data
Declaration, HDTV production standards, international frequency allocations,
expansion of U.S. industry involvement in multi-lateral negotiations, and the
establishment of ministerial bilateral agreements with all major U.S. trading
partners. She was granted the permanent rank of Ambassador for her service in
this capacity. As founder of the Global Information Infrastructure Commission
(GIIC) in cooperation with the World Bank in 1994, Ambassador Dougan launched
the first major global initiative to strengthen private sector leadership and
developing country involvement in advancing the role of telecommunications,
information technologies and services in fostering sustainable development.
Current boards or international advisory positions include: Qualcomm,
Fortis, Centillium, U of California's Graduate School of International
Relations, World Affairs Council, Toyota Motor Corp, IREX (International
Research Exchange Board), the Prime Minister of Malaysia's Multimedia Super
Corridor International Advisory Panel, Schools Online, the new MIT Journal on
Information Technology and International Development, the Department of Public
Enterprise for the Republic of Ireland and the newly formed U.S. State
Department Advisory Task Force on Public Diplomacy in the Arab and Muslim
World.
Early in her career, Ambassador Dougan worked in commercial, cable and
public broadcasting. At age twenty-three she became Time Inc.'s youngest
executive and first CATV Marketing Director (now AOL-Time Warner). Ambassador
Dougan is an award winning television producer including The Nutcracker and
the PBS/NPR special: The MX Debate with Bill Moyers, which won the 1981
Peabody Award "for excellence in broadcast journalism." As a Director of the
Corporation for Public Broadcasting under appointments by both Presidents Ford
and Carter from 1976-1982, she was involved in the development of the first
broadcast satellite network and significantly expanded the programming and
funding base for PBS and NPR. Other media activities have included Chairman,
Editorial Advisory Board Christian Science Monitor TV, a co-founder of the
International Media Fund, and the organizing committee of the Sundance
Institute.
Ambassador Dougan is called on extensively to speak internationally and
has authored or edited over thirty publications dealing with global market,
policy, and political dynamics of information technologies and services. Her
opinion articles have been published in a number of newspapers including the
NEW YORK TIMES, INTERNATIONAL HERALD TRIBUNE, CHRISTIAN SCIENCE MONITOR, LOS
ANGELES TIMES, and KNIGHT RIDDER Newspapers. Her public service and
professional leadership accomplishments have been honored by many awards
including: the Distinguished Service to Journalism Award (University of Utah),
National Security Agency Medal, the Outstanding Women in Communications Award,
AAUW's Utah Women of the Year, WETA, Outstanding Young Women in America and
Distinguished Citizen of Maryland (Governor's Award). In 1965 she was given
the Key to the City of Seoul and made an honorary citizen of Korea. She is
also active with the Council on Foreign Relations, Council of American
Ambassadors, and the Cosmos Club. A graduate of the University of Maryland in
industrial psychology, she pursued additional studies at the University of
Utah in Economics and the Harvard Advanced Management Program.
About Panacea Pharmaceuticals, Inc.
Panacea Pharmaceuticals, Inc. is an emerging biopharmaceutical company
focused on utilizing functional genomics and proteomics to develop
therapeutics and diagnostics for diseases with substantial unmet clinical
need. The Company's product development focus is on novel proteins and
biochemical pathways related to cellular regulation and cell cycle
abnormalities in oncology as well as both acute and chronic neurodegenerative
conditions such as hypoxia-induced cognitive impairment, Parkinson's disease,
and Alzheimer's disease. The Company signed a Collaboration & License
Agreement with MedImmune, Inc. in early 2002 to discover, develop, and
commercialize therapeutic agents for the prevention or treatment of human
disease based on Panacea's HAAH technology or its pathways. The Company's
wholly owned subsidiary, Proteus Diagnostics, Inc., will be developing in
vitro diagnostics including pharmacogenomic and pharmacoproteomic tools for
cancer detection, diagnosis, prognosis, treatment selection, and follow-up.
More information is available at http://www.PanaceaPharma.com .
Except for historical information presented in this press release, matters
discussed herein may constitute "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. Forward-
looking statements are based on the opinions and estimates of management only
as of the date of this release and are subject to certain risks and
uncertainties that could cause actual results to differ materially from any
future results, performance, or achievements expressed or implied by such
statements. Factors that might cause such a difference include, but are not
limited to, uncertainties related to our access to capital, the progress,
costs, and results of any clinical trials undertaken by us, progress of our
research and development projects, and uncertainties related to whether our
product candidates would ultimately achieve commercial success. We do not
undertake any obligation to update publicly any forward-looking statement,
whether as a result of new information, future events, or otherwise unless
required by law.
Contact:
Panacea Pharmaceuticals, Inc.
Kasra Ghanbari, President
Phone 240-243-8000 x108; FAX 240-465-0450
Kasra@PanaceaPharma.com
SOURCE Panacea Pharmaceuticals, Inc.
 back to top
Related links:
http://www.panaceapharma.com
CONTACT:
Kasra Ghanbari, President of Panacea
Pharmaceuticals, Inc., +1-240-243-8000, ext. 108, fax:
+1-240-465-0450, Kasra@PanaceaPharma.com
|
